These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10448770)

  • 1. Cost-effectiveness analysis in clinical practice: the case of heart failure.
    Rich MW; Nease RF
    Arch Intern Med; 1999 Aug 9-23; 159(15):1690-700. PubMed ID: 10448770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effective management of heart failure.
    Parmley WW
    Clin Cardiol; 1996 Mar; 19(3):240-2. PubMed ID: 8674263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing.
    Andersson F; Cline C; Rydén-Bergsten T; Erhardt L
    Pharmacoeconomics; 1999 Jun; 15(6):535-50. PubMed ID: 10538327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
    Smith DG; Cerulli A; Frech FH
    Clin Ther; 2005 Jun; 27(6):951-9. PubMed ID: 16117995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of carvedilol for heart failure.
    Delea TE; Vera-Llonch M; Richner RE; Fowler MB; Oster G
    Am J Cardiol; 1999 Mar; 83(6):890-6. PubMed ID: 10190405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effective way forward for the management of the patient with heart failure.
    Giles T
    Cardiology; 1996; 87 Suppl 1():33-9. PubMed ID: 8681320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Angiotensin-converting enzyme inhibitors in the management of congestive heart failure: a pharmaceutical industry perspective.
    Boccuzzi SJ
    Am Heart J; 1999 May; 137(5):S120-2. PubMed ID: 10220612
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost and cost-effectiveness studies in heart failure research.
    Weintraub WS; Cole J; Tooley JF
    Am Heart J; 2002 Apr; 143(4):565-76. PubMed ID: 11923792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incremental cost-effectiveness of guideline-directed medical therapies for heart failure.
    Banka G; Heidenreich PA; Fonarow GC
    J Am Coll Cardiol; 2013 Apr; 61(13):1440-6. PubMed ID: 23433562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. ACE inhibitors in the management of congestive heart failure: comparative economic data.
    Boyko WL; Glick HA; Schulman KA
    Am Heart J; 1999 May; 137(5):S115-9. PubMed ID: 10220611
    [No Abstract]   [Full Text] [Related]  

  • 11. The pharmacoeconomics of ACE inhibitors in chronic heart failure.
    McMurray J; Davie A
    Pharmacoeconomics; 1996 Mar; 9(3):188-97. PubMed ID: 10160096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From cost of illness to cost-effectiveness in heart failure.
    Lévy E
    Eur Heart J; 1998 Dec; 19 Suppl P():P2-4. PubMed ID: 9886705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomic considerations in assessing and selecting congestive heart failure therapies.
    Levy E; Levy P
    Pharmacoeconomics; 2002; 20(14):963-77. PubMed ID: 12403637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group.
    Sculpher MJ; Poole L; Cleland J; Drummond M; Armstrong PW; Horowitz JD; Massie BM; Poole-Wilson PA; Ryden L
    Eur J Heart Fail; 2000 Dec; 2(4):447-54. PubMed ID: 11113723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost effectiveness of ACE inhibition in therapy of chronic heart failure in Switzerland: evaluation based on the SOLVD study].
    Szucs TD; Goedde M; Berger K; Kiowski W
    Schweiz Med Wochenschr; 1997 Jul; 127(29-30):1234-41. PubMed ID: 9333933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomics of angiotensin converting enzyme inhibitors in heart failure.
    Szucs TD
    Am J Hypertens; 1997 Oct; 10(10 Pt 2):272S-279S. PubMed ID: 9366284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic burden of heart failure: a summary of recent literature.
    Lee WC; Chavez YE; Baker T; Luce BR
    Heart Lung; 2004; 33(6):362-71. PubMed ID: 15597290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost of heart failure to the healthcare system.
    Mackowiak J
    Am J Manag Care; 1998 Jun; 4(6 Suppl):S338-42. PubMed ID: 10184926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economics of treating heart failure.
    Mark DB
    Am J Cardiol; 1997 Oct; 80(8B):33H-38H. PubMed ID: 9372996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Congestive heart failure management program honored for outcomes, cost savings.
    Levenson D
    Rep Med Guidel Outcomes Res; 2001 Nov; 12(22):6-7. PubMed ID: 12389584
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.